Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

Introduction Hepatocellular carcinoma (HCC) is a common cause of cancer-related death, often detected in the intermediate stage. The standard of care for intermediate-stage HCC is transarterial chemoembolisation (TACE), where idarubicin (IDA) is a promising drug. Despite the fact that TACE has been...

Full description

Bibliographic Details
Main Authors: Fredrik Rorsman, Ulrika S H Simonsson, Håkan Ahlström, Sofi Sennefelt Nyman, Angeliki Dimopoulou Creusen, David Dahlgren, Mikael Hedeland, Femke Heindryckx, Ulf Johnson, Jaafar Khaled, Fredrik Kullenberg, Rickard Nyman, Reza Sheikhi, Erik Sjögren, Alkwin Wanders, Hans Lennernäs, Charlotte Ebeling Barbier
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/11/e065839.full

Internet

https://bmjopen.bmj.com/content/12/11/e065839.full

Similar Items